key: cord-0782373-694wrmg2
authors: van Kraaij, Tom DA; Mostard, Rémy LM; Ramiro, Sofia; Magro Checa, Cesar; van Dongen, Christel MP; van Haren, Eric HJ; Buijs, Jacqueline; Landewé, Robert BM
title: Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
date: 2020-04-22
journal: Eur J Case Rep Intern Med
DOI: 10.12890/2020_001675
sha: 40f5fbf6eed2537cbd19bf53bd4f65fa2713a196
doc_id: 782373
cord_uid: 694wrmg2

Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS. LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients. Immunosuppressive therapy may provide important additional therapeutic benefit in these patients. Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome.

LEARNING POINTS • Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients. • Immunosuppressive therapy may provide important additional therapeutic benefit in these patients. • Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome.

KEYWORDS COVID-19, cytokine release syndrome, tocilizumab BACKGROUND Patients admitted with COVID-19 pneumonia are often old with many comorbidities. However, younger patients seem to primarily experience an exaggerated response of their immune system to COVID-19 pulmonary infection, and develop features of cytokine release syndrome (CRS), which may be life threatening [1, 2] .

Thus far, there is no proven antiviral therapy for COVID-19, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS [3] . We describe a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ).

A 26-year-old, previously healthy man was referred to our emergency department on 28 March with a 5-day history of fever, dyspnoea and cough. He walked into the emergency department independently, but within 1 hour needed an oxygen supply of 15 l/min on an OxyMask to maintain his oxygen saturation at 90%. A pulmonary CT scan showed extensive areas of ground-glass opacities and subtle consolidations bilaterally, predominantly in the basal lung areas, with some extension to all pulmonary lobes (CO-RADS 5). A SARS-Corona E-swab PCR test returned a positive result within a few hours. Laboratory testing showed increased levels of C-reactive protein (CRP; 153 µg/ml), ferritin (703 ng/ml) and D-dimer (3233 ng/ml). The diagnosis of COVID-19 pneumonia was made and treatment with chloroquine and prophylactic ceftriaxone and low-molecular weight heparin was initiated.

The patient was admitted to the intensive care unit for treatment with high-flow oxygen (Optiflow, 30 l; 65% FiO 2 ) resulting in a maximum O 2 saturation of 93% and an arterial pO 2 of 61.5 mmHg. On the second day of admission, the patient's respiratory condition further deteriorated and he had to be intubated for invasive ventilation in the prone position. As the extreme clinical deterioration in conjunction with laboratory findings (Fig. 1) raised a high suspicion of CRS, we decided to administer a single intravenous dose of TCZ at a dose of 8 mg/kg body-weight. TCZ is an IL-6-receptor-blocking biological drug commonly used in the treatment of autoimmune disorders such as rheumatoid arthritis.

Initially, CRP, ferritin, D-dimer and IL-6 levels showed a further increase, suggestive of advancing CRS. However, from 31 March onwards (2 days after TCZ administration), ventilation conditions improved day-by-day. This was associated with a reversal of laboratory parameters toward normal levels of CRP, ferritin and IL-6 within 5 days of administration of TCZ. During this period, the patient was weaned from mechanical ventilation and successfully extubated. A chest x-ray performed on 5 April, 7 days after treatment with TCZ, showed complete resolution of abnormalities (Fig. 2) . On 7 April, 9 days after treatment with TCZ, the patient was discharged from hospital without any need for supplemental oxygen.

IL-6 plays a key role in the pathogenesis of CRS, although its contribution has not yet been fully elucidated. TCZ, a biological drug that binds to the IL-6 receptor and prevents IL-6 from signalling, is used successfully in the treatment of autoimmune diseases. It has also been approved for the treatment of severe or life-threatening CRS associated with chimeric antigen receptor (CAR) T-cell immunotherapy in patients with malignancy [4, 5] .

Our case strongly suggests that administration of a single dose of TCZ in advancing SARS-CoV-2-induced CRS (within a hypothesized window of opportunity) contributes to a surprising turnaround in an otherwise damaging clinical course.

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

The coronavirus patients betrayed by their own immune systems. The New York Times

COVID-19: consider cytokine storm syndromes and immunosuppression

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome